References
1. World Health Organization (WHO). Novel Coronavirus (2019-nCoV), Situation Report - 1, 21 January 2020 . WHO; 2020. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200121-sitrep-1-2019-ncov.pdf?sfvrsn=20a99c10_4
2. Gorbalenya AE, Baker SC, Baric RS, et al. Severe acute respiratory syndrome-related coronavirus</em>: The species and its viruses – a statement of the Coronavirus Study Group.bioRxiv . 2020:2020.02.07.937862. doi:10.1101/2020.02.07.937862
3. Mahase E. Covid-19: most patients require mechanical ventilation in first 24 hours of critical care. BMJ . Mar 24 2020;368:m1201. doi:10.1136/bmj.m1201
4. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet . Feb 15 2020;395(10223):497-506. doi:10.1016/S0140-6736(20)30183-5
5. Bhatraju PK, Ghassemieh BJ, Nichols M, et al. Covid-19 in Critically Ill Patients in the Seattle Region - Case Series. N Engl J Med . Mar 30 2020;doi:10.1056/NEJMoa2004500
6. Grasselli G, Pesenti A, Cecconi M. Critical Care Utilization for the COVID-19 Outbreak in Lombardy, Italy: Early Experience and Forecast During an Emergency Response. JAMA . Mar 13 2020;doi:10.1001/jama.2020.4031
7. Kirkland SW, Soleimani A, Rowe BH, Newton AS. A systematic review examining the impact of redirecting low-acuity patients seeking emergency department care: is the juice worth the squeeze? Emerg Med J . Feb 2019;36(2):97-106. doi:10.1136/emermed-2017-207045
8. Rowe BH, Guo X, Villa-Roel C, et al. The role of triage liaison physicians on mitigating overcrowding in emergency departments: a systematic review. Acad Emerg Med . Feb 2011;18(2):111-20. doi:10.1111/j.1553-2712.2010.00984.x
9. Morley C, Unwin M, Peterson GM, Stankovich J, Kinsman L. Emergency department crowding: A systematic review of causes, consequences and solutions. PLoS One . 2018;13(8):e0203316. doi:10.1371/journal.pone.0203316
10. World Health Organization Director. General’s opening remarks at the media briefing on COVID-19 - 24 February 2020 . 2020. Accessed 07 April 2020. https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---24-february-2020
11. Zarin DA, Goodman SN, Kimmelman J. Harms From Uninformative Clinical Trials. JAMA . Jul 25 2019;doi:10.1001/jama.2019.9892
12. Chan AW, Tetzlaff JM, Gotzsche PC, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ . Jan 8 2013;346:e7586. doi:10.1136/bmj.e7586
13. Food and Drug Administration. Surrogate Endpoint Resources for Drug and Biologic Development . 2018. Accessed 10 April 2020. https://www.fda.gov/drugs/development-resources/surrogate-endpoint-resources-drug-and-biologic-development
14. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med . Oct 1 1996;125(7):605-13. doi:10.7326/0003-4819-125-7-199610010-00011
15. Food and Drug Administration. Amendments Act of 2007. Public Law 110-85.
16. Zarin DA, Tse T, Williams RJ, Califf RM, Ide NC. The ClinicalTrials.gov results database–update and key issues. N Engl J Med . Mar 3 2011;364(9):852-60. doi:10.1056/NEJMsa1012065
10.1056/NEJMsa1012065.
17. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res . Mar 2020;30(3):269-271. doi:10.1038/s41422-020-0282-0
18. Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents . Mar 20 2020:105949. doi:10.1016/j.ijantimicag.2020.105949
19. Food and Drug Administration. Request for Emergency Use Authorization For Use of Chloroquine Phosphate or Hydroxychloroquine Sulfate Supplied From the Strategic National Stockpile for Treatment of 2019 Coronavirus Disease . 2020. Accessed 07 April 2020. https://www.fda.gov/media/136534/download
20. Food and Drug Administration. Drugs@FDA: FDA-Approved Drugs: Plaquenil . Accessed 07 April 2020. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=009768
21. Lehoux P, Miller FA, Daudelin G, Denis JL. Providing Value to New Health Technology: The Early Contribution of Entrepreneurs, Investors, and Regulatory Agencies. Int J Health Policy Manag . Sep 1 2017;6(9):509-518. doi:10.15171/ijhpm.2017.11
22. Alexander PE, Debono VB, Mammen MJ, et al. COVID-19 research has overall low methodological quality thus far: case in point for chloroquine/hydroxychloroquine. Journal of Clinical Epidemiology . 2020;doi:10.1016/j.jclinepi.2020.04.016
23. Williamson PR, Altman DG, Bagley H, et al. The COMET Handbook: version 1.0. Trials . Jun 20 2017;18(Suppl 3):280. doi:10.1186/s13063-017-1978-4
24. Bikdeli B, Punnanithinont N, Akram Y, et al. Two Decades of Cardiovascular Trials With Primary Surrogate Endpoints: 1990-2011.J Am Heart Assoc . Mar 21 2017;6(3)doi:10.1161/JAHA.116.005285
25. Yazdany J, Kim AHJ. Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know. Ann Intern Med . Mar 31 2020;doi:10.7326/M20-1334
26. Zarin DA, Tse T, Williams RJ, Carr S. Trial Reporting in ClinicalTrials.gov - The Final Rule. N Engl J Med . Nov 17 2016;375(20):1998-2004. doi:10.1056/NEJMsr1611785
27. CPS [Internet]. Ottawa (ON): Canadian Pharmacists Association; c2016 [updated 2020 April; cited 2020 April 15]. Gleevec [Hydroxychloroquine]. Available from: http://www.e-cps.ca or http://www.myrxtx.ca. Also available in paper copy from the publisher.
28. Mayo-Wilson E, Fusco N, Li T, et al. Harms are assessed inconsistently and reported inadequately part 1: systematic adverse events. J Clin Epidemiol . Sep 2019;113:20-27. doi:10.1016/j.jclinepi.2019.04.022
29. Mayo-Wilson E, Fusco N, Hong H, Li T, Canner JK, Dickersin K. Opportunities for selective reporting of harms in randomized clinical trials: Selection criteria for non-systematic adverse events.Trials . Sep 5 2019;20(1):553. doi:10.1186/s13063-019-3581-3
30. Ghersi D, Pang T. From Mexico to Mali: four years in the history of clinical trial registration. J Evid Based Med . Feb 2009;2(1):1-7. doi:10.1111/j.1756-5391.2009.01014.x